🧪 Divi’s Laboratories Sees Growth on Strong Export Demand & Custom Synthesis

Divi’s Laboratories continues to witness steady growth driven by strong export demand and traction in custom synthesis (CDMO) business. The company is benefiting from long-term contracts with global pharma clients, improving capacity utilisation, and operational efficiency. Focus on high-margin products and cost control is supporting profitability. Management remains optimistic about future growth, backed by robust order pipeline and increasing global outsourcing demand. 📌 StockYard Take: Strong export focus and CDMO growth position Divi’s as a key long-term pharma outperformer. #DivisLab #PharmaStocks #ExportGrowth #CDMO #StockYardResearch